Non-Invasive Prenatal Testing Market (By Product, Gestation Period, Pregnancy Risk, Technology, Application, End User, and Region), Key Company Profiles, Market Dynamics, Trends and Recent Developments - Global Forecast to 2032

The global non-invasive prenatal testing market was valued at USD 5.08 billion in 2025, and is projected to surpass USD 9.85 billion by 2032. Non-invasive prenatal testing (NIPT) is an advanced prenatal screening technique that assesses the risk of fetal chromosomal and genetic abnormalities by analyzing cell-free fetal DNA (cfDNA) circulating in maternal blood. The test is primarily used to screen for common chromosomal disorders, including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), and sex chromosome aneuploidies. Compared with conventional invasive diagnostic procedures such as amniocentesis and chorionic villus sampling (CVS), NIPT provides a safer and highly accurate screening option with virtually no risk of procedure-related miscarriage. It can also be performed as early as 9-10 weeks of gestation, enabling earlier clinical decision-making and pregnancy management.

The market is being driven by the increasing prevalence of chromosomal abnormalities, rising maternal age, and growing awareness of the benefits of early prenatal screening. Expanding clinical applications of NIPT beyond common trisomies to include the detection of microdeletions, rare chromosomal abnormalities, and selected single-gene disorders are further broadening its adoption. Additionally, continuous advancements in next-generation sequencing (NGS) technologies, declining sequencing costs, and improvements in bioinformatics are enhancing the accuracy, accessibility, and clinical utility of NIPT. Favorable reimbursement policies, supportive government initiatives promoting prenatal screening, and the growing preference for non-invasive diagnostic approaches are also contributing significantly to the growth of the global NIPT market.

Recent Developments

• In August 2025, Natera launched Fetal Focus, In August 2025, Natera launched Fetal Focus, a new noninvasive prenatal test that screens fetal DNA from maternal blood for cystic fibrosis and three other inherited single-gene conditions, achieving over 90% accuracy in preliminary trials. This test is especially useful when the baby's father is unavailable for genetic testing. Supported by the EXPAND trial involving about 1,300 pregnant women, Fetal Focus detects recessive conditions such as cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies, providing critical prenatal information without invasive procedures.
• In October 2024, Yourgene Health, part of the Novacyt Group and a leading provider of molecular diagnostics solutions, partnered with Genetix, a high-tech genetic diagnostics company, to launch Colombia's first locally available non-invasive prenatal testing (NIPT) service. Powered by Yourgene's IONA Nx NIPT Workflow, Genetix's NipTest delivers safe, rapid, and highly accurate prenatal screening by enabling local sample processing. The collaboration significantly reduces test turnaround times, eliminates the need for international sample shipment, and improves access to advanced prenatal genetic screening for expectant parents across Colombia.

By Product: Global Non-Invasive Prenatal Testing Market - Key Takeaways

• By product, consumables & reagents dominated the global non-invasive prenatal testing (NIPT) market in 2025, owing to their indispensable and recurring use in every testing procedure. The high volume of repeat purchases by diagnostic laboratories and healthcare facilities, coupled with the growing number of NIPT tests performed worldwide, continues to drive strong demand for consumables and reagents.
• The instruments segment accounted for over one-quarter of the global non-invasive prenatal testing (NIPT) market in 2025, supported by the increasing adoption of advanced next-generation sequencing (NGS) platforms, automated laboratory systems, and high-throughput diagnostic instruments. Continuous technological advancements and expanding laboratory infrastructure are further contributing to the growth of this segment.

By Gestation Period: Global Non-Invasive Prenatal Testing Market - Key Takeaways

• By gestation period, the 13-24 weeks segment dominated the global non-invasive prenatal testing (NIPT) market in 2025, as it represents the most widely utilized timeframe for prenatal screening. This stage offers an optimal balance between adequate fetal cell-free DNA (cfDNA) concentration and high test accuracy, making it the preferred window for NIPT adoption among healthcare providers and expectant mothers. Additionally, many pregnancies are first evaluated comprehensively during the second trimester, further supporting the segment's leading market share.
• The 0-12 weeks gestation segment is projected to be the fastest-growing segment during the forecast period, driven by increasing demand for early prenatal risk assessment, growing awareness of the benefits of first-trimester screening, and continuous advancements in NIPT technologies that enable reliable testing from as early as 9-10 weeks of pregnancy. Rising maternal age and the emphasis on early clinical decision-making are further accelerating the adoption of NIPT during early gestation.
• The 25-36 weeks gestation segment accounted for a comparatively smaller share of the global non-invasive prenatal testing (NIPT) market in 2025, as NIPT is less commonly performed during the later stages of pregnancy. Testing during this period is generally reserved for delayed prenatal care, follow-up evaluations, or pregnancies requiring additional genetic assessment after inconclusive or abnormal earlier screening results.

By Pregnancy Risk: Global Non-Invasive Prenatal Testing Market - Key Takeaways

• Based on pregnancy risk, the high- and average-risk pregnancy segment dominated the global non-invasive prenatal testing (NIPT) market in 2025, driven by strong clinical adoption, well-established screening guidelines, and the higher prevalence of chromosomal abnormalities among these patient populations. Widespread physician recommendations, favorable reimbursement policies in several countries, and the routine use of NIPT in pregnancies with elevated genetic risk have further strengthened the segment's market leadership.
• The low-risk pregnancy segment is projected to be the fastest-growing category during the forecast period, supported by the expanding clinical acceptance of universal prenatal screening, increasing awareness of the benefits of early fetal genetic assessment, and updated professional guidelines recommending NIPT for pregnancies regardless of baseline risk. Growing affordability and broader access to prenatal screening services are also accelerating adoption among low-risk expectant mothers.

By Technology: Global Non-Invasive Prenatal Testing Market - Key Takeaways

• In terms of technology, Next-Generation Sequencing (NGS) dominated the global non-invasive prenatal testing (NIPT) market in 2025, owing to its high analytical accuracy, broad genomic coverage, and ability to simultaneously detect multiple chromosomal abnormalities. NGS platforms support scalable, high-throughput workflows, making them well suited for large diagnostic laboratories and centralized testing facilities while enabling continuous expansion into advanced prenatal screening applications.
• The array technology segment accounted for a notable share of the market, primarily due to its application in targeted genetic testing, particularly for the detection of sub-chromosomal abnormalities, copy number variations (CNVs), and selected microdeletion syndromes. Although its adoption is more specialized than NGS, array-based technologies remain valuable in specific clinical scenarios requiring detailed genomic analysis.
• The polymerase chain reaction (PCR) segment is expected to register the fastest growth during the forecast period, driven by its cost-effectiveness, rapid turnaround time, and suitability for targeted prenatal screening applications. Ongoing advancements in PCR-based molecular diagnostics, coupled with increasing demand for affordable and decentralized testing solutions, are expected to further support the growth of this segment.

By Application: Global Non-Invasive Prenatal Testing Market - Key Takeaways

• By application, the trisomy detection segment is expected to remain the largest contributor to the global non-invasive prenatal testing (NIPT) market throughout the forecast period. The segment's dominance is driven by the widespread clinical adoption of NIPT for screening common chromosomal abnormalities, including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Strong recommendations from clinical guidelines, high diagnostic accuracy, and increasing demand for early prenatal screening continue to support the segment's leading market position.
• The microdeletion syndrome segment is projected to be the fastest-growing application area in the global non-invasive prenatal testing (NIPT) market during the forecast period. Growth is being driven by expanding clinical applications of NIPT, increasing awareness of rare genetic disorders, and continuous advancements in sequencing technologies that improve the detection of sub-chromosomal abnormalities. Rising demand for comprehensive prenatal genetic screening and ongoing research validating the clinical utility of microdeletion testing are expected to further accelerate the growth of this segment.

By End User: Global Non-Invasive Prenatal Testing Market - Key Takeaways

• In terms of end users, diagnostic laboratories dominated the global non-invasive prenatal testing (NIPT) market in 2025, primarily due to their advanced laboratory infrastructure, access to high-throughput sequencing platforms, and specialized expertise in molecular and genetic diagnostics. These facilities process a high volume of samples with greater efficiency and accuracy, making them the preferred setting for NIPT services.
• The hospitals & clinics segment accounted for a significant share of the global non-invasive prenatal testing (NIPT) market, driven by the increasing integration of NIPT into routine prenatal care and obstetric practices. Hospitals and clinics serve as the primary point of patient engagement, offering prenatal consultations, sample collection, genetic counseling, and comprehensive pregnancy management.

By Region: Global Non-Invasive Prenatal Testing Market - Key Takeaways

• By region, North America dominated the global non-invasive prenatal testing (NIPT) market in 2025, driven by the region's advanced healthcare infrastructure, widespread adoption of genomic and molecular diagnostic technologies, and strong presence of leading NIPT providers. Favorable reimbursement policies, high awareness of prenatal genetic screening, increasing maternal age, and supportive clinical guidelines have further contributed to the region's market leadership.
• Europe accounted for a significant share of the global NIPT market, with countries such as Germany, the United Kingdom, and France leading regional adoption. Growth is supported by well-established prenatal screening programs, expanding access to genetic testing services, favorable reimbursement frameworks in several countries, and increasing integration of NIPT into routine prenatal care.
• Asia Pacific is projected to be the fastest-growing regional market over the forecast period, driven by rising healthcare expenditure, increasing maternal age, growing awareness of prenatal genetic screening, and improving access to advanced diagnostic technologies. Expanding healthcare infrastructure, government initiatives to enhance maternal and fetal health, a large birth population, and the growing availability of cost-effective NIPT services are expected to accelerate market expansion across countries such as China, Japan, India, South Korea, and Australia.

The report provides a comprehensive analysis of the Global Non-Invasive Prenatal Testing Market.

This report has been analyzed from 13 View Points:

1) Global - Non-Invasive Prenatal Testing Market and Forecast (2021 - 2032)
2) Global - Non-Invasive Prenatal Testing Market Share and Forecast (2021 - 2032)
3) By Product - Global Non-Invasive Prenatal Testing Market and Forecast (2021 - 2032)
4) By Gestation Period - Global Non-Invasive Prenatal Testing Market and Forecast (2021 - 2032)
5) By Pregnancy Risk - Global Non-Invasive Prenatal Testing Market and Forecast (2021 - 2032)
6) By Technology - Global Non-Invasive Prenatal Testing Market and Forecast (2021 - 2032)
7) By Application - Global Non-Invasive Prenatal Testing Market and Forecast (2021 - 2032)
8) By End User - Global Non-Invasive Prenatal Testing Market and Forecast (2021 - 2032)
9) By Region - Global Non-Invasive Prenatal Testing Market and Forecast (2021 - 2032)
10) Global Non-Invasive Prenatal Testing Market - Recent Developments
11) Global Non-Invasive Prenatal Testing Market - Trends
12) Global Non-Invasive Prenatal Testing Market - Key Company Profiles
13) Global Non-Invasive Prenatal Testing Market - Market Dynamics

By Product - Non-Invasive Prenatal Testing Market and Forecast

• Consumables & Reagents
• Instruments

By Gestation Period - Non-Invasive Prenatal Testing Market and Forecast

• 0-12 Weeks
• 13-24 Weeks
• 25-36 Weeks

By Pregnancy Risk - Non-Invasive Prenatal Testing Market and Forecast

• High & Average Risk
• Low Risk

By Technology - Non-Invasive Prenatal Testing Market and Forecast

1. NGS
2. Array Technology
3. PCR
4. Others

By Application - Non-Invasive Prenatal Testing Market and Forecast

• Trisomy Detection
• Microdeletion Syndrome
• Others

By End User - Non-Invasive Prenatal Testing Market and Forecast

• Diagnostic Laboratories
• Hospitals & Clinics

By Region - Non-Invasive Prenatal Testing Market & Forecast

1. North America

• United States
• Canada

2. Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Netherlands

3. Asia Pacific

• Japan
• China
• India
• Australia
• South Korea

4. Latin America

• Brazil
• Mexico
• Argentina

5. Middle East & Africa

• South Africa
• Saudi Arabia
• UAE

Global Non-Invasive Prenatal Testing Market - Key Company Profiles

1. BillionToOne, Inc.
2. Revvity, Inc.
3. Illumina, Inc.
4. Natera, Inc.
5. Qiagen N.V.
6. Labcorp Holdings Inc.
7. Eurofins Scientific SE
8. Apollo Hospitals Enterprise Limited
9. BGI Genomics Co., Ltd.
10. IHH Healthcare Berhad